- Home
- Prof Carolyn Lam
Carolyn Lam
National Heart Centre Singapore Duke-NUS, Singapore, SG
Biography
Prof Carolyn Lam is a Senior Consultant Cardiologist and Director of Women’s Heart Health at the National Heart Centre Singapore, where she pioneered the country’s first Women’s Heart Clinic. Internationally recognised for her expertise in heart failure with preserved ejection fraction (HFpEF), Prof Lam has played a key role in landmark clinical trials including PARAGON-HF, EMPEROR-Preserved, DELIVER and FINEARTS-HF.
Her work helped establish the first FDA-approved treatment for HFpEF and the first trial to demonstrate robust clinical benefit in this patient population. A prolific researcher, Prof Lam has authored over 700 peer-reviewed publications in top journals such as New England Journal of Medicine, Lancet, JAMA, Circulation and European Heart Journal. She was named a Clarivate Highly Cited Researcher in Clinical Medicine from 2021 to 2024.
Prof Lam is also a deputy editor of the Journal of the American College of Cardiology (JACC) and served on the 2021–2022 ESC Heart Failure Guidelines Task Force. In digital health, she co-founded Us2.ai, a MedTech startup using artificial intelligence to automate echocardiography and improve access to heart disease diagnosis worldwide.
Featured Courses
- 1.00
Published:
Learning objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors